Document Detail


Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study).
MedLine Citation:
PMID:  21094366     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Retrospective studies have suggested a beneficial effect of lipid-lowering treatment on the progression of aortic stenosis (AS) in milder stages of the disease. In the randomized, placebo-controlled Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study, 4.3 years of combined treatment with simvastatin 40 mg and ezetimibe 10 mg did not reduce aortic valve events (AVEs), while ischemic cardiovascular events (ICEs) were significantly reduced in the overall study population. However, the impact of baseline AS severity on treatment effect has not been reported. Baseline and outcomes data in 1,763 SEAS patients (mean age 67 years, 39% women) were used. The study population was divided into tertiles of baseline peak aortic jet velocity (tertile 1: ≤ 2.8 m/s; tertile 2: > 2.8 to 3.3 m/s; tertile 3: > 3.3 m/s). Treatment effect and interaction were tested in Cox regression analyses. The rates of AVEs and ICEs increased with increasing baseline severity of AS. In Cox regression analyses, higher baseline peak aortic jet velocity predicted higher rates of AVEs and ICEs in all tertiles (all p values < 0.05) and in the total study population (p < 0.001). Simvastatin-ezetimibe treatment was not associated with a statistically significant reduction in AVEs in any individual tertile. A significant quantitative interaction between the severity of AS and simvastatin-ezetimibe treatment effect was demonstrated for ICEs (p < 0.05) but not for AVEs (p = 0.10). In conclusion, the SEAS study results demonstrate a strong relation between baseline the severity of AS and the rate of cardiovascular events but no significant effect of lipid-lowering treatment on AVEs, even in the group with the mildest AS.
Authors:
Eva Gerdts; Anne Bjørhovde Rossebø; Terje Rolf Pedersen; Kurt Boman; Philippe Brudi; John Boyd Chambers; Kenneth Egstrup; Christa Gohlke-Bärwolf; Ingar Holme; Y Antero Kesäniemi; William Malbecq; Christoph Nienaber; Simon Ray; Terje Skjærpe; Kristian Wachtell; Ronnie Willenheimer
Related Documents :
15259896 - Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplificat...
12780746 - The effects of soy protein containing isoflavones on lipids and indices of bone resorpt...
2170516 - Is a high serum cholesterol level associated with longer survival in elderly hypertensi...
16755446 - Effects of preoperative statin therapy on cytokines after cardiac surgery.
11296186 - Long-term intermittent dobutamine infusion combined with oral amiodarone improves the s...
17963846 - Patterns of response to repetitive transcranial magnetic stimulation (rtms) in major de...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2010-10-14
Journal Detail:
Title:  The American journal of cardiology     Volume:  106     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-24     Completed Date:  2011-01-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1634-9     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2010. Published by Elsevier Inc.
Affiliation:
Institute of Medicine, University of Bergen, Bergen, Norway. eva.gerdts@helse-bergen.no
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Aortic Valve Stenosis / blood,  diagnosis*,  drug therapy
Azetidines / administration & dosage,  therapeutic use*
Disease Progression
Dose-Response Relationship, Drug
Drug Therapy, Combination
Echocardiography
Female
Follow-Up Studies
Humans
Hypolipidemic Agents / administration & dosage,  therapeutic use*
Lipids / blood*
Male
Middle Aged
Prospective Studies
Severity of Illness Index
Simvastatin / administration & dosage,  therapeutic use*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Azetidines; 0/Hypolipidemic Agents; 0/Lipids; 163222-33-1/ezetimibe; 79902-63-9/Simvastatin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Long-term risk of aortic events following aortic valve replacement in patients with bicuspid aortic ...
Next Document:  Effect of implantable cardioverter-defibrillator on left ventricular ejection fraction in patients w...